SCHEMBL6448401

SCHEMBL6448401

CCCCC/C=C/C(=O)CCCCC

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 4/20 0.82
PPARA Q07869 4/20 0.82
KDM4E B2RXH2 1/20 0.64
TERT O14746 3/20 0.59
PTPN1 P18031 3/20 0.59
CYP1A2 P05177 2/20 0.59
MAPT P10636 2/20 0.59
CYP2C19 P33261 2/20 0.59
BLM P54132 2/20 0.59
HSD17B10 Q99714 2/20 0.59
FABP4 P15090 2/20 0.59
FAAH O00519 2/20 0.59
KMT2A Q03164 2/20 0.59
PPARD Q03181 2/20 0.59
GMNN O75496 1/20 0.59
USP2 O75604 1/20 0.59
LMNA P02545 1/20 0.59
POLB P06746 1/20 0.59
CYP2C9 P11712 1/20 0.59
ALOX15 P16050 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2599317 1.00 PPARG (0.82) PPARGPPARAKDM4ETERTPTPN1
SCHEMBL29120297 0.98 PPARG (0.86) PPARGPPARAKDM4ETERTPTPN1
SCHEMBL8593649 0.98 PPARG (0.86) PPARGPPARAKDM4ETERTPTPN1
SCHEMBL18489891 0.98 PPARG (0.86) PPARGPPARAKDM4ETERTPTPN1
SCHEMBL812752 0.98 PPARG (0.86) PPARGPPARAKDM4ETERTPTPN1
SCHEMBL812753 0.98 PPARG (0.86) PPARGPPARAKDM4ETERTPTPN1
SCHEMBL8460772 0.98 PPARG (0.86) PPARGPPARAKDM4ETERTPTPN1
SCHEMBL8593645 0.98 PPARG (0.86) PPARGPPARAKDM4ETERTPTPN1
SCHEMBL28945778 0.98 PPARG (0.86) PPARGPPARAKDM4ETERTPTPN1
SCHEMBL26968801 0.96 PPARG (0.83) PPARGPPARAKDM4ETERTPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115624544-A Application of chalcone analogue as active substance in preparation of antitumor drugs 甘肃中医药大学 2023-01-20 CN disclosed
US-11413278-B2 Compounds and methods for promoting stress resistance THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-08-16 US disclosed
US-20180289682-A1 COMPOUNDS AND METHODS FOR PROMOTING STRESS RESISTANCE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2018-10-11 US disclosed
EP-2571843-B1 IMPROVED PREPARATION OF CHALCONE DERIVATIVES GENFIT (FR) 2017-12-27 EP disclosed
CN-104803927-B Chalcone analog of the base containing 2 methyl, 4 oxoquinazolin 6 and its production and use 首都师范大学 2017-11-07 CN disclosed
WO-2017062751-A1 COMPOUNDS AND METHODS FOR PROMOTING STRESS RESISTANCE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-04-13 WO disclosed
CN-104803927-A Chalcone analogue containing 2-methyl-4-oxo-quinazoline-6-base, and preparation method and application thereof UNIV CAPITAL NORMAL 2015-07-29 CN disclosed
US-8765992-B2 Preparation of chalcone derivatives GENFIT (FR) 2014-07-01 US disclosed
US-20130131372-A1 PREPARATION OF CHALCONE DERIVATIVES GENFIT (FR) 2013-05-23 US disclosed
US-20050203170-A1 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof AVENTIS PHARMA S.A. 2005-09-15 US disclosed
US-20040147597-A1 Anti-mycobacterium compositions and methods of preparing and using same ADVANCED LIFE SCIENCES, INC. 2004-07-29 US disclosed
US-20040147584-A2 1,3-DIARYLPROP-2-EN-1-ONES, COMPOSITIONS CONTAINING THEM AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2004-07-29 US disclosed
WO-2003048106-A3 1,3-DIARYLPROP-2-EN-1-ONES, COMPOSITIONS CONTAINING SAME AND USE THEREOF AVENTIS PHARMA SA (FR) 2004-03-25 WO disclosed
US-6677350-B1 ADMINISTERING CHALCONE-LIKE VINYLCARBONYL COMPOUNDS TO PREVENT OR TREAT MYCOBACTERIUM INFECTIONS/TUBERCULOSIS ADVANCED LIFE SCIENCES, INC. 2004-01-13 US disclosed
US-20030153611-A1 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof AVENTIS PHARMA S.A. 2003-08-14 US disclosed
US-20030153611-A1 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof AVENTIS PHARMA S.A. 2003-08-14 US disclosed
US-20030153611-A1 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof AVENTIS PHARMA S.A. 2003-08-14 US disclosed
WO-2003048106-A2 1,3-DIARYLPROP-2-EN-1-ONES, COMPOSITIONS CONTAINING SAME AND USE THEREOF AVENTIS PHARMA S.A. (FR) 2003-06-12 WO disclosed
EP-1217995-A2 ANTI-MYCOBACTERIUM COMPOSITIONS AND METHODS OF PREPARING AND USING SAME Advanced Life Sciences Inc. (US) 2002-07-03 EP disclosed
WO-2001021164-A2 ANTI-MYCOBACTERIUM COMPOSITIONS AND METHODS OF PREPARING AND USING SAME ADVANCED LIFE SCIENCES, INC. (US) 2001-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147584-A2 1,3-DIARYLPROP-2-EN-1-ONES, COMPOSITIONS CONTAINING THEM AND USE THEREOF MCL1, ENPP1, MYC PPARG 2299/4885PPARA 1360/4885KDM4E 1899/4885
US-20180289682-A1 COMPOUNDS AND METHODS FOR PROMOTING STRESS RESISTANCE HSPA9, ATF4, GPX4 PPARG 1199/4885PPARA 1380/4885KDM4E 4057/4885
US-20040147597-A1 Anti-mycobacterium compositions and methods of preparing and using same IMMT, CYP51A1, LSS PPARG 410/4885PPARA 955/4885KDM4E 2116/4885
US-20050203170-A1 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof MCL1, ENPP1, MYC PPARG 2299/4885PPARA 1360/4885KDM4E 1899/4885
US-20130131372-A1 PREPARATION OF CHALCONE DERIVATIVES SULT1E1, HCCS, STS PPARG 1812/4885PPARA 1760/4885KDM4E 838/4885
US-11413278-B2 Compounds and methods for promoting stress resistance HSPA9, ATF4, GPX4 PPARG 1199/4885PPARA 1380/4885KDM4E 4057/4885
US-20030153611-A1 1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof MCL1, ENPP1, MYC PPARG 2299/4885PPARA 1360/4885KDM4E 1899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.